Lesotho vs Tajikistan: Average cost of multi drug-resistant tuberculosis treatment
Lesotho
81 constant 2022 US$
in 2024
Tajikistan
257 constant 2022 US$
in 2024
Lesotho rank
92nd
Tajikistan rank
90th
Average cost of multi drug-resistant tuberculosis treatment over time
- Lesotho
- Tajikistan
How they compare
Tajikistan currently reports 257 constant 2022 US$ against 81 constant 2022 US$ in Lesotho, a difference of 176 constant 2022 US$.
That makes Tajikistan's figure about 3.2 times Lesotho's.
The two have swapped places 3 times across 6 shared years of data; in 2018 it was Lesotho ahead.
Lesotho ranks 92nd and Tajikistan ranks 90th of 92 countries.
Lesotho has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Lesotho | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,016 constant 2022 US$ | 2,826 constant 2022 US$ | 189 constant 2022 US$ | Lesotho |
| 2020s | 2,762 constant 2022 US$ | 1,983 constant 2022 US$ | 779 constant 2022 US$ | Lesotho |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Lesotho or Tajikistan?
- Tajikistan, at 257 constant 2022 US$ against 81 constant 2022 US$ in Lesotho as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Lesotho and Tajikistan?
- 176 constant 2022 US$, with Tajikistan ahead.
- How many years of comparable data are there for Lesotho and Tajikistan?
- 6 years are reported by both, from 2018 to 2024.
- How do Lesotho and Tajikistan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Lesotho ranks 92nd and Tajikistan ranks 90th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.